Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetrachloroethylene (also known as perchloroethylene or PCE) is a chlorinated hydrocarbon and volatile organic compound (VOC) widely used as an industrial solvent, particularly in dry-cleaning and metal degreasing. Historically, tetrachloroethylene was utilized as an oral anthelmintic (vermifuge) for the treatment of hookworm infestations (such as *Necator americanus* and *Ancylostoma duodenale*) in both humans and animals. Its anthelmintic mechanism of action is non-specific, acting as a cellular poison and anesthetic that paralyzes the parasites, allowing them to be expelled from the gastrointestinal tract. In the body, tetrachloroethylene is metabolized by cytochrome P450 enzymes (primarily CYP2E1) to trichloroacetic acid (TCA), which acts as an agonist of the peroxisome proliferator-activated receptor alpha (PPAR-α). Chronic exposure to tetrachloroethylene is associated with significant hepatotoxicity, including liver fibrosis and an increased risk of hepatocellular carcinoma, mediated in part by oxidative stress and PPAR-α activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetrachloroethylene.